Moderna, Inc.

As of June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh carries a market capitalization of 141.78B, placing it among publicly traded companies globally. Its enterprise value stands at 121.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh has 7.97B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.25, and the price-to-book ratio stands at 4.06.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 121.88B versus a market cap of 141.78B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.04, indicating elevated leverage, while an interest coverage ratio of -73.31 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh posted a negative return on equity (ROE) of -39.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.43, reflecting losses generated across the asset base. The company generates approximately 2.30M in revenue per employee across its workforce of 4,975.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.57 indicates how many times Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh recorded 330.82M in income tax expense. The company reported a pretax loss of -15.96B and -16.29B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh's stock has gained approximately 624.04% over the past 52 weeks. The 50-day moving average sits at 42.24, while the 200-day moving average is 20.61.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh generated 11.42B in revenue and converted that into -16.29B in net income, yielding earnings per share of -2.07. EBITDA reached -15.92B, while operating income came in at -17.16B.

As of June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh holds 26.56B in cash and equivalents against 6.65B in total debt, resulting in a net debt position of -5.85B. Total book value stands at 34.95B, with working capital of 16.96B providing operational flexibility.

Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh produced -5.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -883.90M in capital expenditures, free cash flow totaled -6.43B - equivalent to -0.82 per share.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh posted a gross margin of 22.76, reflecting its pricing power and cost economics. The operating margin of -150.23 and net profit margin of -142.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.23, meaning Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh's most recent stock split took place on November 21, 2022 with a 1:2 split ratio.

As of June 30, 2026, Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh has an Altman Z-Score of 4.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.